Monitoring and evaluation of efficacy and safety of Pyronaridine-Artesunate for the treatment with a low single dose of Primaquine of uncomplicated Plasmodium falciparum malaria in Cambodia

It is a single arm open-label study to evaluate therapeutic efficacy and safety of Pyronaridine-Artesunate for the treatment of Plasmodium falciparum malaria. Eligible patients were treated with a daily dose of 1 tablet for the patients 20-<24 kg body weight, 2 tablets for 24-<45 kg body weight, 3 tablets for 45-<65 kg body weight and 4 tablets for the patients over 65 kg over 3 days. One tablet contains 60mg artesunate plus 18 mg pyronaridine. The patients took the drugs in front of the field-based medical doctor. A full dose was repeated if a patient vomited within 30 minutes following the drug administration. The patients had a blood smear examined by microscope on a daily basis until they were negative on 2 consecutive days. The patients were to visit the study site once a week over 42 days. The patient's home visit was conducted when any patient did not come as the appointment schedule.